Last updated on November 2019

Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months


Brief description of study

The purpose of this study is to evaluate the efficacy of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in WD patients aged 12 and older.

Clinical Study Identifier: NCT03403205

Find a site near you

Start Over

Austin Health

Heidelberg, Australia
3.47miles
  Connect »

Royal Melbourne Hospital

Parkville, Australia
4.79miles
  Connect »

Alfred Hospital

Melbourne, Australia
6.21miles
  Connect »